Chief Executive Officer
Albert D. Bender, Ph.D.
Dr. Bender is a successful serial entrepreneur who has started and has provided the strategic vision and leadership for 4 high technology companies. Three of these venture backed companies achieved technical leadership and growth to enable their sale at a good return for the venture capital and angel investors. During his career, Dr. Bender has raised 10 rounds of venture capital totaling more than $150M. He also has a working relationship with major venture capital partners in North America. His start-up approach is hands-on and focused on practical, workable solutions that produce measurable results. In his career, Dr. Bender has proven successes, leading organizations and activities in the areas of: business strategy; optimizing business operations; technology; sales and marketing; and raising capital.
President/Chief Scientific Officer
Bruce J. Oberhardt, Ph.D.
Dr. Oberhardt has led and/or participated in a number of first-of-a-kind technological developments including “CoaguChek” and founded Cardiovascular Diagnostics: a successful IPO. Major focus areas have included the development of and consulting in multidisciplinary and disruptive technologies, especially involving: blood, cell analysis, immunodiagnostics, fluidic systems, instrumentation, and medical devices including drug delivery systems, in addition to solving problems associated with the intersection of biomedical technology and business. He served in management positions for major multinational medical products manufacturers and developed technologies to help in diabetes, blood diseases, cardiovascular disease, and cancer. Products based on these technologies are currently saving patients’ lives daily.
Board of Directors
William P. Peters, MD, PhD, MBA.
Dr. Peters was the Chief Executive Officer and Chairman of the Board of Adherex, a clinical stage oncology drug company, from 2003, to 2009. Formerly Dr. Peters served on the faculty at Harvard University, Duke University and Wayne State University. He originated the solid tumor high-dose chemotherapy and bone marrow transplant program at the Dana-Farber Cancer Institute, and was Director of Bone Marrow Transplantation and Professor of Medicine at Duke University from 1984 to 1995 and was also an Associate Director of the Cancer Center. He then became President, Director and CEO of the Karmanos Cancer Institute from 1995 to 2001. Simultaneously, he served as Associate Dean for Cancer at Wayne State University and Senior Vice President for Cancer Services at the Detroit Medical Center. Dr. Peters has three Bachelor's degrees (Biochemistry, Biophysics and Philosophy) from Pennsylvania State University, received his MPhil, MD and PhD degrees from Columbia University College of Physicians & Surgeons in New York, and trained clinically at Harvard University Medical School's Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA. He is board certified in internal medicine and medical oncology. Dr. Peters earned his MBA at the Duke University Fuqua School of Business.
Founder/ Scientific Advisor
Professor Stefan Franzen, Ph.D.
Professor of Chemistry North Carolina State University. For over 5 years Professor Franzen has studied, under multiple NIH and NSF grants, the use of the plant virus nanoparticles for cell targeting and drug delivery applications and is co-inventor of the licensed intellectual property. He has led the research that has developed the protocols for loading the nanoparticle, attaching targeting compounds to the outside and studying the safety and efficacy of targeted therapeutics for multiple cancer indications. For the past 10 years he has studied a wide variety of nanoparticle delivery options and published early papers on gold nanoparticle research.
Founder/ Scientific Advisor
Professor Steven Lommel, Ph.D.
Professor of Plant Pathology, Professor of Genetics, Assistant Vice-Chancellor for Research North Carolina State University. Professor Lommel's primary research program is in the areas of plant virology, plant viral pathogenesis and plant genomics. Professor Lommel has researched the red clover necrotic mosaic virus (RCNMV), the plant virus on which the PVN is based, for 29 years. He is considered the world’s expert on this plant virus. Currently the three themes comprising his research program are: i) the molecular mechanism of plant virus movement. ii) Structure of the plant virus nanoparticle. iii) The tobacco genome initiative. Professor Lommel is co-inventor of the licensed technology.
Professor William C. Zamboni, Pharm D, PhD
UNC GLP Analytical Facility. Dr. Zamboni research focuses on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimization of the chemotherapeutic treatment of cancer and on the development of nanoparticle anticancer agents and evaluating the relationship between the disposition of these agents and the reticuloendothelial system.